Bringing a new drug to market is never an easy task. It takes decades of brutal hard work and grind to make it possible. Ever wondered how long it takes? The journey from a laboratory concept to a pharmacy shelf generally takes over 10 years and costs around $2 billion. So, not only is it time-consuming, but it's super expensive.

Identifying a single, effective, and safe molecule among the billions of potential chemical combinations is like chasing rainbows. The pharma industry is going through a transformational phase, and we are in an era of "Silicon Scientists". Advanced machine learning and artificial intelligence models are scanning enormous amounts of data to uncover patterns in human biology and cellular chemistry that were generally invisible to the human eye.

Also read || Is an IQ Test a Real Measure of Intelligence?

The 90% Clinical Failure Wall Remains Untouched.

Machine learning has become so great that you need days instead of years to identify target proteins and generate promising chemical structures. However, when these compounds leave the computer and enter clinical trials, they hit a familiar brutal wall. 

According to Dr. Hao Zhu of Rutgers University, modern drug development is operating in a "big data era". Nevertheless, it has not brought a slight change in fundamental clinical success rates. Traditional computational and laboratory models still have major limitations, such as very low correlations to actual drug activities in living organisms. This usually occurs when evaluating the therapeutic efficacy and side effects of complex treatments. 

Dr. Hao Zhu stated that while the use of in vitro (laboratory) and in silico (computational) protocols can reduce drug attrition cases, their results show very low correlation with drug activities in the lab for efficacy and complex effects. That is the reason why nine out of ten drug candidates still fail to advance from Phase I clinical trials to final regulatory approval. In short, AI can help with work more quickly but cannot change the laws of human biology.

We Are Starving for High-Quality, "Machine-Ready" Data

While there is a good inflow of data in the life sciences, clean, unbiased, and structured data remains scarce. And without clean, machine-ready data, you can't train machine learning models and expect them to perform reliably. According to a Chemical and Engineering News report, researchers are often bottlenecked by the "garbage-in, garbage-out" dilemma.

Many existing machine learning models are trained on small, error-prone public training datasets or on highly biased high-throughput screening (HTS) data, which contain far more inactive negative responses than active positive ones. Dr. Nevan Krogan of the Quantitative Biosciences Institute at UCSF emphasized that hype often hides the technical reality of drug discovery.

Besides, industry experts such as Chris Meier of the Boston Consulting Group (BCG) and Panna Sharma of Lantern Pharma note that massive amounts of legacy research data remain trapped in static PDFs and unstructured literature instead of being structured into "machine-ready" databases.

No Fully AI-Designed Drug Has Been Approved—Yet

Despite eye-grabbing headlines and spectacular initial public offerings, the pharmaceutical industry has yet to witness its first historic milestone: a fully AI-designed, discovered, and approved drug. According to a BCG study, dozens of AI-first biotechnology pipelines have advanced to clinical trials, but none have been approved for clinical use.

The prominent chemist and industry expert, Derek Lowe, revealed a surprising pattern. In his critical analysis of 67 AI-generated molecules, 24 were directed at targets labeled "AI-discovered". However, he pointed out that most "novel" targets are already well-documented and often have FDA-approved treatments on the market.

AI undoubtedly excels at optimizing chemical compounds, but you can not discover entirely new therapeutic targets. Instead, you can use it as a tool to explore the unexplored biological spaces. In this journey, startups like Lantern Pharma and Benevolent AI are successfully shortening preclinical timelines, bringing candidates to Phase I and II trials. However, the proof of clinical efficacy is still to be revealed. 

Also read || Vitamin B12 Deficiency in 2026: Signs, Tests & Treatment

Proteins Are "Wiggling" Targets, Not Static Locks

Computational chemists relied on static protein models, treating them like rigid locks waiting for a perfectly shaped molecular key. And it happened for decades. However, cellular biology is not static; it's very dynamic and incredibly chaotic. In Relay Therapeutics research, proteins were observed to be constantly moving, sliding, and "wiggling" through a spectrum of physical shapes within the crowded cell environment.

Relay's CEO, Sanjiv Patel, believes that their machine learning platform must be trained on biophysical and structural data to predict these shifting physical shapes or conformations, and target pockets where medicines can bind. Moreover, Dr. Avner Schlessinger of Mount Sinai notes that even AlphaFold has structural limitations.

AlphaFold might have been a Nobel Prize-winning tool, but it's not perfect. They are heavily trained on static snapshots from the Protein Data Bank, which fail to capture the flexible, active confirmations required to bind compounds with optimal, drug-like behavior in real-world systems.

Human Intuition and Wet-Lab Validation Are Irreplaceable

The most comforting reality for human scientists and researchers is that artificial intelligence is not a replacement for humans. It can be a great accelerator or a tool, but not a substitute. According to Dr. Friedrich Rippmann, automated design lacks the critical "inventive step" of human creativity.

It also leads to major intellectual property and legal challenges, as high courts in regions such as the United Kingdom have ruled that AI cannot be named as the sole inventor on a patent application. Besides, AI models are inherently uncreative and rely on historical datasets, which makes it difficult to conduct new research.

Jamie Robertson of Harvard Medical School seconds these thoughts and highlights that algorithms heavily rely on strictly historical training databases and struggle to generate genuinely novel research hypotheses or to account for personal experiences. Without human chemists, prediction and evaluation of computer-designed compound synthesis is pragmatically difficult.

Also read || Atkins Diet: Is it a Fad or Real Deal?

What's next for the future?

Data science and AI are helping biopharmaceutical giants like AstraZeneca transform siloed data into Findable, Accessible, Interoperable, and Reusable (FAIR) assets. They are using advanced machine learning techniques, such as knowledge graphs and multi-omics, to overcome human confirmation bias and uncover new, hidden biological patterns. 

The future of drug discovery is not about an independent scientist working in a siloed environment or a vacuum. It would need powerful collaboration in which machines handle the heavy lifting of scale and pattern recognition. At the same time, humans will always be required for essential intuition, biological context, and real-world confirmation. In simpler terms, human biology is stubborn, and AI cannot entirely substitute for human scientists.